1. Home
  2. CLBR vs INO Comparison

CLBR vs INO Comparison

Compare CLBR & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLBR
  • INO
  • Stock Information
  • Founded
  • CLBR 2023
  • INO 1979
  • Country
  • CLBR United States
  • INO United States
  • Employees
  • CLBR N/A
  • INO N/A
  • Industry
  • CLBR
  • INO Medical/Dental Instruments
  • Sector
  • CLBR
  • INO Health Care
  • Exchange
  • CLBR Nasdaq
  • INO Nasdaq
  • Market Cap
  • CLBR 218.8M
  • INO 203.3M
  • IPO Year
  • CLBR 2023
  • INO 1998
  • Fundamental
  • Price
  • CLBR $10.22
  • INO $6.28
  • Analyst Decision
  • CLBR
  • INO Buy
  • Analyst Count
  • CLBR 0
  • INO 6
  • Target Price
  • CLBR N/A
  • INO $21.33
  • AVG Volume (30 Days)
  • CLBR 63.4K
  • INO 286.5K
  • Earning Date
  • CLBR 01-01-0001
  • INO 08-08-2024
  • Dividend Yield
  • CLBR N/A
  • INO N/A
  • EPS Growth
  • CLBR N/A
  • INO N/A
  • EPS
  • CLBR N/A
  • INO N/A
  • Revenue
  • CLBR N/A
  • INO $591,858.00
  • Revenue This Year
  • CLBR N/A
  • INO N/A
  • Revenue Next Year
  • CLBR N/A
  • INO N/A
  • P/E Ratio
  • CLBR $130.99
  • INO N/A
  • Revenue Growth
  • CLBR N/A
  • INO N/A
  • 52 Week Low
  • CLBR $9.16
  • INO $3.84
  • 52 Week High
  • CLBR $10.48
  • INO $14.75
  • Technical
  • Relative Strength Index (RSI)
  • CLBR N/A
  • INO 26.00
  • Support Level
  • CLBR N/A
  • INO $6.33
  • Resistance Level
  • CLBR N/A
  • INO $7.56
  • Average True Range (ATR)
  • CLBR 0.00
  • INO 0.40
  • MACD
  • CLBR 0.00
  • INO -0.06
  • Stochastic Oscillator
  • CLBR 0.00
  • INO 8.47

About CLBR Colombier Acquisition Corp. II

Colombier Acquisition Corp II is a blank check company.

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Share on Social Networks: